Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort

The incidence of neutropenia in metastatic castration‐resistant prostate cancer (mCRPC) patients treated with docetaxel has been reported to be lower compared to patients with other solid tumors treated with a similar dose. It is suggested that this is due to increased clearance of docetaxel in mCRP...

Descripción completa

Detalles Bibliográficos
Autores principales: de Vries Schultink, Aurelia H. M., Crombag, Marie‐Rose B. S., van Werkhoven, Erik, Otten, Hans‐Martin, Bergman, Andre M., Schellens, Jan H. M., Huitema, Alwin D. R., Beijnen, Jos H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488109/
https://www.ncbi.nlm.nih.gov/pubmed/30802002
http://dx.doi.org/10.1002/cam4.2003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488109/
https://www.ncbi.nlm.nih.gov/pubmed/30802002
http://dx.doi.org/10.1002/cam4.2003

Ejemplares similares